Biotech entity
Every one of those 1 sits in a single category, pharma. Simoa is most often covered alongside Akoya, which appears in 1 of these 1 story. The tracked stories average 6 original sources each. Simoa appears in 1 tracked Biotech story from March 4, 2026.
Last mentioned: Mar 4, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Simoa is most often covered alongside Akoya, which appears in 1 of these 1 story. The tracked stories average 6 original sources each. Simoa appears in 1 tracked Biotech story from March 4, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Simoa. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 Earnings
Company reports 25% total revenue growth and progress in clinical diagnostic pivot.
FDA 510(k) Submission
Premarket notification submitted for Lucent AD Complete diagnostic test.
CMS Reimbursement Milestone
CMS approves $897 reimbursement rate for Lucent AD Complete, establishing a national reference price.
Assay Portfolio Expansion
Launch of 13 new assays including pTau-205 and pTau-212 for neurodegenerative research.
Quanterix reported Q4 2025 revenue of $43.9 million, driven by a 25% year-over-year increase and significant progress in its Alzheimer’s diagnostic portfolio. Despite organic declines in its core Simoa and Spatial segments, the company secured a $897 CMS reimbursement rate for its Lucent AD Complete test and submitted its 510(k) to the FDA.
Simoa is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
